Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman

Key Takeaways

• Geopolitical tension in Strait of Hormuz raises risk for vaccine shipments
• Single‑source suppliers amplify disruption risk across pharmaceutical industry
• Buffer inventory and multi‑source strategy cut expiry‑related losses
• AI analytics map supplier origins, enabling proactive diversification decisions
• Collaborative vendor shortlisting beats price‑only RFPs for long‑term value

Pulse Analysis

Geopolitical flashpoints such as the Iran‑related tension in the Strait of Hormuz are reshaping the pharmaceutical supply chain in real time. The region funnels a substantial share of active pharmaceutical ingredients, vaccines, and insulin to global markets, and any disruption reverberates through shipping lanes already strained by container shortages and higher freight rates. As vessels become scarcer, manufacturers face rising landed costs and longer lead times, prompting a reassessment of how critical drugs are sourced and delivered worldwide.

Procurement teams are now turning to diversification and inventory buffering as core defenses. Golfman stresses that relying on a single supplier—whether for a high‑value oncology drug or a short‑shelf‑life vaccine—creates a single point of failure that can quickly translate into stockouts or expired products. By conducting geographic audits of supplier footprints and maintaining several weeks to months of safety stock, companies can absorb transit delays and price spikes. AI‑driven platforms further enhance visibility, flagging at‑risk origins and modeling cost‑impact scenarios, enabling faster, data‑backed decisions that mitigate exposure to geopolitical shocks.

Beyond technology, the conversation is shifting toward more collaborative procurement models. Traditional RFPs that chase the lowest price often ignore hidden costs such as longer payment terms, quality variance, or extended lead times. Golfman recommends shortlisting a few vetted vendors and co‑creating solutions that balance cost, reliability, and compliance. This partnership approach not only reduces the race to the bottom but also builds strategic resilience, positioning pharma firms to maintain steady drug supplies even amid escalating global uncertainties.